SPRB · XBRL financial data
Spruce Biosciences financial statements, every fiscal year
The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (SPRB's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 10,089 | 4,911 | 0 |
| Research and development | 23,854 | 30,698 | 35,198 | 49,432 | 46,418 | 19,522 |
| General and administrative | 5,562 | 11,368 | 12,085 | 12,650 | 14,644 | 16,991 |
| Total operating expenses | 29,416 | 42,066 | 47,283 | 62,082 | 61,062 | 36,513 |
| Operating income (loss) | (29,416) | (42,066) | (47,283) | (51,993) | (56,151) | (36,513) |
| Interest expense | 323 | 345 | 420 | 483 | 307 | 90 |
| Other income (expense) | 200 | 119 | — | — | — | — |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income (loss) | (29,539) | (42,292) | (46,180) | (47,919) | (53,036) | (38,966) |
| Earnings per share, basic USD per share | — | (1.81) | (1.96) | (1.24) | (1.29) | (50.83) |
| Earnings per share, diluted USD per share | — | (1.81) | (1.96) | (1.24) | (1.29) | (50.83) |
| Weighted average shares, basic thousands of shares | — | 23,361 | 23,527 | 38,510 | 41,265 | 767 |
| Weighted average shares, diluted thousands of shares | — | 23,361 | 23,527 | 38,510 | 41,265 | 767 |
- † Share count changed about 1/31 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (SPRB's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 157,150 | 42,748 | 24,487 | 96,339 | 38,753 | 48,906 |
| Short-term investments | — | 46,221 | 54,590 | 0 | — | — |
| Accounts receivable | — | — | 0 | — | — | — |
| Prepaid and other current assets | — | 2,926 | — | — | — | — |
| Total current assets | 160,397 | 91,895 | 83,608 | 102,183 | 44,206 | 52,112 |
| Property and equipment, net | 73 | 140 | — | — | — | — |
| Right-of-use asset | 1,793 | 1,479 | 1,400 | — | — | — |
| Total assets | 162,883 | 126,486 | 85,648 | 103,946 | 45,209 | 53,021 |
| Accounts payable | 3,628 | 2,823 | 1,426 | 3,332 | 1,295 | 943 |
| Accrued liabilities | — | — | — | 14,600 | 12,329 | 9,143 |
| Current portion of long-term debt | 2,554 | 0 | 1,622 | 1,622 | 1,622 | 0 |
| Total current liabilities | 9,763 | 8,871 | 12,447 | 24,465 | 15,246 | 10,086 |
| Long-term debt | 1,922 | 4,878 | 3,293 | 1,717 | 124 | 0 |
| Lease liability, non-current | 1,653 | 1,293 | 1,261 | 1,019 | 736 | 419 |
| Total liabilities | 13,456 | 15,115 | 17,162 | 27,437 | 16,388 | 10,505 |
| Accumulated deficit | (60,841) | (103,133) | (149,313) | (197,232) | (250,268) | (289,234) |
| Total stockholders' equity | 149,427 | 111,371 | 68,486 | 76,509 | 28,821 | 42,516 |
| Total liabilities and equity | 162,883 | 126,486 | 85,648 | 103,946 | 45,209 | 53,021 |
| Common shares outstanding (cover page) thousands of shares | 23,302 | 23,493 | 39,746 | 41,149 | 42,231 | 1,372 |
- † Share count changed about 1/31 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (SPRB's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (29,539) | (42,292) | (46,180) | (47,919) | (53,036) | (38,966) |
| Stock-based compensation | 755 | 3,958 | 3,631 | 4,622 | 5,348 | 2,574 |
| Depreciation and amortization | 36 | 68 | — | — | — | — |
| Net cash from operating activities | (27,519) | (35,877) | (41,683) | (33,275) | (55,964) | (33,327) |
| Purchases of property and equipment | 74 | 93 | 8 | 7 | 0 | — |
| Net cash from investing activities | (74) | (79,168) | 23,692 | 55,777 | 0 | — |
| Proceeds from long-term debt | — | 4,990 | 0 | — | — | — |
| Repayments of long-term debt | — | 4,770 | 0 | 1,622 | 1,622 | 2,057 |
| Net cash from financing activities | 181,035 | 643 | (241) | 49,140 | (1,622) | 43,481 |
- † Share count changed about 1/31 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Spruce Biosciences | 96,295 | not reported | (22,120)* | 2.9M | 4.4 quarters | 10-QJun 30, 2026 |
| Propanc Biopharma | 832 | not reported | (1,602)* | 6.3M | 0.5 quarters | 10-KJun 30, 2026 |
| MetaVia | 12,634 | not reported | (3,762)* | 6.6M | 3.4 quarters | 10-QJun 30, 2026 |
| Cannapharmarx | 0.6 | 276 | (127)* | 708.7M | 0.0 quarters | 10-QJun 30, 2026 |
| Oragenics | 3,864 | not reported | (2,187)* | 4.5M | 1.8 quarters | 10-QJun 30, 2026 |
| Inhibitor Therapeutics | 516 | not reported | (775)* | 173.8M | 0.7 quarters | 10-QJun 30, 2026 |
| PTC Therapeutics | 508,894 | 357,807 | (25,311)* | 83.5M | — | 10-QSep 30, 2026 |
| Integrated Biopharma | 4,471 | not reported | (1,194)* | 31.1M | 3.7 quarters | 10-KJun 30, 2026 |
| Enveric Biosciences | 8,296 | not reported | (2,445)* | 4.5M | 3.4 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.